全球血管生成抑制剂市场 – 行业趋势及 2029 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

全球血管生成抑制剂市场 – 行业趋势及 2029 年预测

  • Pharmaceutical
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 页面
  • 桌子數: 220
  • 图号: 60

>全球血管生成抑制剂市场,按产品(VEGF 靶向治疗、FGF 靶向治疗、致癌基因靶向治疗、基质降解和重塑靶向治疗等)、适应症(胶质母细胞瘤、结直肠癌等)、药物(Inlyta、Avastin、Revlimid 等)、给药途径(口服、肠外和其他)、最终用户(医院、专科诊所等)、分销渠道(医院药房、零售药房等)划分 - 行业趋势和预测(至 2029 年)

血管生成抑制剂市场

全球血管生成抑制剂市场分析与洞察

不同类型的癌症患病率高,影响人数众多,预计将帮助血管生成抑制剂市场在预测期内实现巨大增长。此外,由于 COVID-19 突然爆发造成的限制影响,预计市场在预测期内将出现负增长。

  • Data Bridge Market Research 分析,在 2022 年至 2029 年的预测期内,血管生成抑制剂市场将以 9.20% 的复合年增长率增长。预测期内,“VEGF 靶向治疗”占血管生成抑制剂市场的产品部分。

全球血管生成抑制剂市场定义

新血管的形成被称为血管生成。抗血管生成药物,也称为血管生成抑制剂,是阻断血管生成过程的物质。这些药物对某些癌症的治疗至关重要。血管生成抑制剂与其他抗癌药物不同,它们阻止支持肿瘤生长的血管生长,而不是阻止肿瘤细胞生长。

血管生成抑制剂市场动态

驱动程序

  • 癌症病例不断增加 

全球范围内乳腺癌、前列腺癌、肺癌等癌症负担的不断加重将导致治疗市场增长率的扩大。

此外,研发投资产生新疗法也是推动市场增长的决定因素。此外,治疗方案的可用性和潜在药物的强大渠道将进一步促进血管生成抑制剂市场的增长。

此外,医疗技术的进步和化疗副作用的增加是扩大血管生成抑制剂市场的关键因素。其他因素,如对有效治疗程序的需求增加,将对血管生成抑制剂市场的增长率产生积极影响。

机会

此外,政府提高癌症意识的举措将为市场增长率带来新的机会。此外,医疗技术的发展也将在未来提高血管生成抑制剂市场的增长率。

Restraints/Challenges Global Angiogenesis Inhibitors Market

However, the high cost of the inhibitor will impede the growth rate of angiogenesis inhibitors market. Additionally, the stringent government regulations hampers the market growth.

This angiogenesis inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on angiogenesis inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Angiogenesis inhibitors, are substances that block the process of angiogenesis.  The annual cancer cases are expected rise from14 million to 22 million in next two decades.

Angiogenesis inhibitors market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Angiogenesis Inhibitors Market

The senior population with underlying severe therapeutic conditions, including people with cancer along with the patients with hepatocellular carcinoma might be at higher risk for severe illness from COVID-19 thus influencing market at a high level. Pharmaceutical industries were heavily impacted by the COVID-19. The angiogenesis inhibitors market was however affected negatively by the sudden emergence of the COVID-19, due to suspended of various operations which are not emergency cases as a result of several government restrictions. Moreover, the disruption in supply chain causing delays in the import and export of drugs and medicines for the angiogenesis inhibitors also further creates hurdles for the expansion of the market.

Recent Developments

  • 2020 年 6 月,生物技术公司 Targovax 与 Leidos 的全球健康探索 (ExGloH) 部门合作,研究 Targovax 的溶瘤腺病毒临床项目 ONCOS 是否可以用作编码 MicrotideT 检查点抑制剂肽的载体。MicrotideTM 是 Leidos 的全球健康探索 (ExGloH) 部门开发的专有微生物衍生肽组合,可作为免疫检查点抑制剂。Leidos 是一家总部位于美国的国防、航空、信息技术和生物医学研究公司。

全球血管生成抑制剂市场范围

血管生成抑制剂市场根据产品、适应症、药物、给药途径、最终用户和分销渠道进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场,并为用户提供有价值的市场概览和市场洞察,帮助他们做出战略决策,确定核心市场应用。

产品

  • VEGF靶向治疗
  • FGF 靶向治疗
  • 癌基因靶向治疗
  • 基质降解与重塑靶向治疗
  • 其他的

根据产品,血管生成抑制剂市场细分为 VEGF 靶向治疗、FGF 靶向治疗、致癌基因靶向治疗、基质降解和重塑靶向治疗等。预计 VEGF 靶向治疗领域在预测期内将以最快的复合年增长率增长。

指征

根据适应症,血管生成抑制剂市场分为胶质母细胞瘤、结直肠癌和其他。

给药途径

  • 口服
  • 肠外
  • 其他的

根据给药途径,血管生成抑制剂市场分为口服、肠外和其他。

最终用户

  • 医院
  • 专科诊所
  • 其他的

根据最终用户,血管生成抑制剂市场分为医院、专科诊所和其他。

分销渠道

  • 医院药房
  • 零售药店
  • 其他的

根据分销渠道,血管生成抑制剂市场分为医院药房、零售药房和其他。

血管生成抑制剂市场区域分析/见解

对血管生成抑制剂市场进行了分析,并按国家、产品、适应症、药物、给药途径、最终用户和分销渠道提供了市场规模洞察和趋势,如上所述。

血管生成抑制剂市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

就市场份额和市场收入而言,北美在血管生成抑制剂市场中占据主导地位,并将在预测期内继续保持主导地位。这是由于该国癌症发病率不断上升、主要市场参与者的存在以及新产品的推出影响了该地区的市场增长。另一方面,预计亚太地区在预测期内将呈现最高增长率,原因是人们对早期诊断的认识不断提高、医疗支出增长、患者未满足的临床需求很高以及该地区中国和印度等新兴国家的有效治疗等因素。

报告的国家部分还提供了影响单个市场因素和国内市场法规变化,这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、疾病流行病学和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外,在对国家数据进行预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、销售渠道的影响。

竞争格局和血管生成抑制剂市场份额分析

血管生成抑制剂市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对血管生成抑制剂市场的关注有关。

血管生成抑制剂市场的一些主要参与者包括 F. Hoffmann-La Roche Ltd、辉瑞公司、Exelixis, Inc、诺华公司、武田制药有限公司、Melinta Therapeutics LLC、Cipla Inc.、太阳制药工业有限公司、百时美施贵宝公司、Balaji Medical Services Private Limited、礼来公司、拜耳公司、赛诺菲和默克公司等。

研究方法:全球血管生成抑制剂市场

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。市场份额分析和关键趋势分析也是市场报告中的主要成功因素。要了解更多信息,请请求分析师致电或提出您的询问。DBMR 研究团队使用的关键研究方法是数据三角测量,其中包括数据挖掘、数据变量对市场影响的分析以及主要(行业专家)验证。除此之外,数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息,请向我们的行业专家咨询 https://www.databridgemarketresearch.com/zh/speak-to-analyst/?dbmr=global-angiogenesis-inhibitors-market


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Angiogenesis Inhibitors Market is projected to grow at a CAGR of 9.20% during the forecast period by 2029.
The Angiogenesis Inhibitors Market is segmented on the basis of product, indication, drugs, route of administration, end-users and distribution channel.
The major players in the Angiogenesis Inhibitors Market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Exelixis, Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Melinta Therapeutics LLC, Cipla Inc., Sun Pharmaceutical Industries Ltd., etc.
The countries covered in the Angiogenesis Inhibitors Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, etc.